Author Topic: (ECTRIMS2018) Rituximab for MS doesn't increase cancer risk compared to Gilenya, Tysabri  (Read 37 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8223
  • MS diagnosed 1980
  • Location: Pacific Northwest

Presented at the 2018 ECTRIMS conference in Berlin (October 10-12)--"Cancer risk among Swedish multiple sclerosis patients:  A nationwide cohort study comparing rituximab, fingolimod, and natalizumab":

http://www.professionalabstracts.com/ectrims2018/iplanner/#/presentation/293


Note: In the abstract, IR = Incidence Ratio



« Last Edit: October 12, 2018, 08:32:02 am by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8223
  • MS diagnosed 1980
  • Location: Pacific Northwest
An article about these findings in Multiple Sclerosis News Today (October 12, 2018)--"Rituximab cancer risk in MS compared to Gilenya, Tysabri":


https://multiplesclerosisnewstoday.com/2018/10/11/ectrims2018-rituximab-cancer-risk-ms-compared-gilenya-tysabri/
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
49 Views
Last post August 03, 2016, 04:04:30 pm
by agate
0 Replies
41 Views
Last post May 17, 2017, 09:58:16 am
by agate
1 Replies
43 Views
Last post October 17, 2017, 03:57:08 pm
by agate
0 Replies
27 Views
Last post December 13, 2017, 02:44:44 pm
by agate
0 Replies
31 Views
Last post August 23, 2018, 09:16:15 pm
by agate